×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Bayer raps GI study

Published on .

A press release from Bayer Corp., Parsippany, N.J., took aim at a study on gastrointestinal bleeding being presented at a American College of Gastroenterology meeting in New York, saying it was sponsored by a competitor and unfairly cites aspirin and other OTC anti-inflammatory remedies. The survey "is funded by McNeil Consumer Products, the makers of Tylenol," Bayer said. "McNeil's attempt to make an issue over aspirin and other non-steroidal anti-inflammatory drugs gastrointestinal side effects is a tactic to deflect attention from the questionable safety of acetaminophen--the key ingredient in Tylenol." And the Aspirin Foundation of America said the study "inappropriately misconstrues the safety record of aspirin."

In this article:
Most Popular